Agenus Inc
AGEN5.400USD
+0.040+0.75%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
143.44MCap. mercado
PérdidaP/E TTM
Más Datos de Agenus Inc Compañía
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Información de la empresa
Símbolo de cotizaciónAGEN
Nombre de la empresaAgenus Inc
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoDr. Garo H. Armen, Ph.D.
Número de empleados316
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 04
Dirección3 Forbes Rd
CiudadLEXINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02421-7305
Teléfono17816744400
Sitio Webhttps://agenusbio.com/
Símbolo de cotizaciónAGEN
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoDr. Garo H. Armen, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Mr. Timothy R. (Tim) Wright
Mr. Timothy R. (Tim) Wright
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Mr. Timothy R. (Tim) Wright
Mr. Timothy R. (Tim) Wright
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
23.56M
97.88%
Rest of world
510.00K
2.12%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
Estadísticas de accionistas
Actualizado: jue., 10 de jul
Actualizado: jue., 10 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.24%
BlackRock Institutional Trust Company, N.A.
5.86%
B. Riley Financial, Inc
2.76%
Geode Capital Management, L.L.C.
1.98%
Invus Public Equities Advisors, LLC
1.82%
Other
78.33%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.24%
BlackRock Institutional Trust Company, N.A.
5.86%
B. Riley Financial, Inc
2.76%
Geode Capital Management, L.L.C.
1.98%
Invus Public Equities Advisors, LLC
1.82%
Other
78.33%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
23.00%
Investment Advisor/Hedge Fund
7.24%
Research Firm
2.79%
Individual Investor
1.94%
Pension Fund
0.59%
Bank and Trust
0.11%
Family Office
0.10%
Hedge Fund
0.05%
Other
64.18%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
332
9.76M
35.62%
-3.10M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
2023Q1
387
12.07M
75.08%
+236.97K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
2.55M
9.3%
+140.69K
+5.84%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
5.86%
+103.10K
+6.85%
Mar 31, 2025
B. Riley Financial, Inc
756.96K
2.76%
+756.96K
--
Dec 31, 2024
Geode Capital Management, L.L.C.
544.14K
1.98%
+68.55K
+14.41%
Mar 31, 2025
Invus Public Equities Advisors, LLC
500.00K
1.82%
+500.00K
--
Mar 31, 2025
State Street Global Advisors (US)
480.75K
1.75%
-5.96K
-1.23%
Mar 31, 2025
AQR Capital Management, LLC
441.49K
1.61%
+427.60K
+3080.28%
Mar 31, 2025
Morgan Stanley & Co. LLC
369.40K
1.35%
+34.14K
+10.18%
Mar 31, 2025
Armen (Garo H.)
319.09K
1.16%
+68.31K
+27.24%
Jun 27, 2025
BofA Global Research (US)
200.35K
0.73%
+93.23K
+87.03%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0%
SPDR S&P Biotech ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.03%
iShares Russell 2000 Growth ETF
Proporción0%
SPDR S&P Biotech ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Fidelity Enhanced Small Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Fecha
Tipo
Relación
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
